The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.
 
Myles Ingram
No Relationships to Disclose
 
Brianna N Lauren
No Relationships to Disclose
 
Yoanna S Pumpalova
No Relationships to Disclose
 
Gulam Abbas Manji
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - Exelixis; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Susan Elaine Bates
Research Funding - Agios
Patents, Royalties, Other Intellectual Property - Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst)
 
Chin Hur
Stock and Other Ownership Interests - Cambridge Biomedical and Economic Consulting Group
Honoraria - Kite, a Gilead company